There are 2867 resources available
583P - Aurora kinase overexpression may play a role in PARPi resistance in tumor samples of patients with high grade ovarian cancer and its inhibition with alisertib overcomes resistance to olaparib in a PARPi-resistant cell line model
Presenter: Jose Alejandro Perez Fidalgo
Session: Poster session 09
584P - Mutation analysis of ovarian carcinoma patients presenting optimal response to neoadjuvant chemotherapy
Presenter: Elizabeth Dos Santos
Session: Poster session 09
585P - Trabectedin induces apoptosis regardless of acquired resistance to PARP inhibitors in BRCA2 mutant high grade ovarian cancer cell lines
Presenter: Jose Alejandro Perez Fidalgo
Session: Poster session 09
586P - BRCA1, BRCA2 and RAD51C somatic RNAseq study in ovarian cancer: A description of physiological and pathogenic splicing patterns
Presenter: Molka SEBAI
Session: Poster session 09
587P - Sequential approach to determine the HRD status with BRCA1 promotor methylation status and shallow whole genome sequencing (sWGS)
Presenter: Etienne Rouleau
Session: Poster session 09
588P - Prognostic value of circulating tumor DNA (ctDNA) in ovarian cancer
Presenter: Jinho Heo
Session: Poster session 09
589P - Circulating tumour DNA as prognostic factor in endometrial cancer: Updated results from an international multicenter study
Presenter: Franziska Siegenthaler
Session: Poster session 09
590P - Ki67 as a predictor of response to PARP inhibitors in platinum sensitive BRCA wild type ovarian cancers: MITO 37 retrospective study
Presenter: Valentina Tuninetti
Session: Poster session 09
591P - Feasibility of longitudinal monitoring of whole blood-based circulating tumour DNA (ctDNA) in patients with endometrial cancer
Presenter: Yoo-Na Kim
Session: Poster session 09
592P - Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer
Presenter: Ursula Matulonis
Session: Poster session 09